

Rabbit anti-Human EXOSC2 Polyclonal Antibody | anti-EXOSC2 antibody

Anti-EXOSC2 Antibody, Rabbit Polyclonal


CATALOG #	HOST	REACTIVITY	APPLICATIONS
AAA256389	Rabbit	Human	Immunoprecipitation, Immunohistochemistry, Western Blot

PRODUCT SYNONYMS


EXOSC2; Polyclonal Antibody; Anti-EXOSC2 Antibody; Rabbit Polyclonal; EXOSC2 Antibody; Rabbit PAb; Antigen Affinity Purified; exosome component 2; Anti-hRrp4p Antibody; Anti-p7 Antibody; Anti-RRP4 Antibody; Anti-Rrp4p Antibody; anti-EXOSC2 antibody

PRODUCT SPECIFICATIONS


Host	Rabbit
Reactivity	Human
Clonality	Polyclonal
Isotype	Rabbit IgG
Specificity	Human EXOSC2
Purity/Purification	Protein A & Antigen Affinity
Form/Format	Liquid; PBS, pH7.0 with 0.03% Proclin300
Applicable Applications for anti-EXOSC2 antibody	IP (Immunoprecipitation), IHC (Immunohistochemistry), WB (Western Blot)
Immunogen	E Coli-derived Human EXOSC2 fragment
Conjugation	Unconjugated
Preparation	Produced in rabbits immunized with E Coli-derived Human EXOSC2 fragment, and purified by antigen affinity chromatography.
Preparation and Storage	This antibody can be stored at 2-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 degree C to -80 degree C. Avoid repeated freeze-thaw cycles.




IP (Immunoprecipitation)
EXOSC2 was immunoprecipitated using: Lane A: 0.5 mg Jurkat Whole Cell Lysate 4 uL anti-EXOSC2 rabbit polyclonal antibody and 60 ug of Immunomagnetic beads Protein A/G. Primary antibody: Anti-EXOSC2 rabbit polyclonal antibody, at 1:100 dilution Secondary antibody: Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution Developed using the ECL technique. Performed under reducing conditions. Predicted band size: 33 kDa Observed band size :33 kDa



IHC (Immunohistochemistry)
Immunochemical staining of human EXOSC2 in human liver with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.



IHC (Immunohistochemistry)
Immunochemical staining of human EXOSC2 in human kidney with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.



WB (Western Blot)
Anti-EXOSC2 rabbit polyclonal antibody at 1:500 dilution Lane A: 293T Whole Cell Lysate Lane B: Hela Whole Cell Lysate Lane C: Jurkat Whole Cell Lysate Lysates/proteins at 30 ug per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size: 33 kDa Observed band size: 33 kDa

ADDITIONAL INFORMATION

Related Product Information for anti-EXOSC2 antibody	Missense mutations in the RNA exosome component 2 (EXOSC2), also known as ribosomal RNA-processing protein 4 (RRP4), were recently identified in two unrelated families with a novel syndrome known as Short stature, Hearing loss, Retinitis pigmentosa, and distinctive Facies (SHRF). EXOSC2 encodes the 'ribosomal RNA-processing protein 4' (RRP4)-one of the core components of the RNA exosome. The RNA exosome is a multiprotein complex that plays key roles in RNA processing and degradation. Mutations in the RNA exosome gene EXOSC2 cause a distinct syndrome with various tissue-specific phenotypes including retinitis pigmentosa, hearing loss, and mild intellectual disability. Retinitis pigmentosa in combination with hearing loss can be a feature of different Mendelian disorders.
References	Yang X, et al. (2020) Genetic and genomic studies of pathogenic exosc2 mutations in the newly described disease shrf implicate the autophagy pathway in disease pathogenesis. Hum Mol Genet 29 (4): 541-553. Morton DJ, et al. (2018) The rna exosome and rna exosome-linked disease. Rna 24 (2): 127-142. Di Donato N, et al. (2016) Mutations in exosc2 are associated with a novel syndrome characterised by retinitis pigmentosa, progressive hearing loss, premature ageing, short stature, mild intellectual disability and distinctive gestalt. J Med Genet 53 (6): 419-425.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.